GSK Spinout BHV Seeks Funds For Phase II Diabetes Drug

Developing diabetes drugs is no easy task. It's even harder if a start-up has to convince venture capitalists it can clear the FDA's high diabetes hurdles. And it's harder still if the FDA has just rejected a drug with the same mechanism of action.